<DOC>
	<DOCNO>NCT01613950</DOCNO>
	<brief_summary>The study intend investigate safety BYL719 AUY922 patient advance gastric cancer , determine MTD and/or RDE drug combination . In addition , preliminary efficacy BYL719 combination AUY922 , pharmacokinetics drug assess . Patients eligible study , tumor carry either molecular alteration PIK3CA , amplification HER2 . The study include dose escalation part follow safety expansion phase .</brief_summary>
	<brief_title>PI3K Inhibitor BYL719 Combination With HSP90 Inhibitor AUY922 Patients With Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Patients advance metastatic adenocarcinoma stomach gastroesophageal junction ; Patients must complete gastrectomy ; gastric tumor carry PIK3CA mutation amplification , HER2overexpression , ; least one three previous line treatment advance metastatic disease ; Patients PIK3CA mutate amplified tumor must fail least one line three line standard chemotherapy and/or target agent ; Patients HER2 amplify tumor must fail least one line , three line , without antiHER2 therapy . All HER2 positive patient expect received trastuzumab unless contraindication present trastuzumab unavailable ; Performance Status ( PS ) ≤ 1 ; Adequate bone marrow , liver organ function laboratory parameter ; Recovery AEs previous anticancer therapy , include surgery radiotherapy , baseline CTCAE Grade ≤ 1 , except alopecia ; Negative serum pregnancy ( β hCG ) test within 72 hr start study treatment premenopausal woman woman &lt; 12 month onset menopause . * Progressive disease prior combination treatment PI3Kinhibitors HSP90 inhibitor ; history prior significant toxicity another PI3K HSP90 inhibitor require discontinuation treatment ; primary CNS tumor uncontrolled CNS metastasest ; Patients currently receive medication know risk prolong QT interval induce Torsades de Pointes treatment either discontinue switched different medication prior start study drug treatment ; Patients diabetes mellitus require insulin treatment and/or clinical sign fast glucose ≥ 140 mg/dL / 7.8 mmol/L , history clinically significant gestational diabetes mellitus document steroidinduced diabetes mellitus ; Patients diarrhea CTCAE Grade ≥ 2 ; Patients acute chronic pancreatitis ; History current evidence central serous retinopathy ( CSR ) , retinal vein occlusion ( RVO ) ophthalmopathy assess ophthalmologic examination baseline would consider risk factor CSR/RVO ; Impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption oral BYL719 ; Patients receive chronic slowrelease formulation Proton Pump Inhibitors ( PPI ) , H2antagonists gastric pH elevate agent ; Treatment therapeutic dos coumarinbased anticoagulant ( e.g. , warfarin sodium , Coumadin® ) . Low dos courmarinbased anticoagulant ; Patients receive chronic high dose corticosteroid therapy ; protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gastric cancer advance gastric metastatic gastric cancer PI3K PIK3CA mutation Her2 amplification HSP90 inhibitor PI3K inhibitor PIK3CA amplification</keyword>
</DOC>